SCYX Latest Press Releases

-- November 5, 2026 --

SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 8:20 AM

-- October 29, 2026 --

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference Globe Newswire 8:00 AM

-- October 22, 2026 --

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases Globe Newswire 8:00 AM

-- October 21, 2026 --

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek Globe Newswire 4:05 PM

-- October 6, 2026 --

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Globe Newswire 7:30 AM

-- September 28, 2026 --

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247 Globe Newswire 7:30 AM

-- September 22, 2026 --

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors Globe Newswire 8:00 AM

-- September 15, 2026 --

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development Globe Newswire 8:00 AM

-- September 10, 2026 --

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer Globe Newswire 8:00 AM

-- September 1, 2026 --

SCYNEXIS to Participate in Upcoming Investor Conferences Globe Newswire 8:30 AM

-- August 25, 2026 --

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:06 PM

-- August 10, 2026 --

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:30 PM

-- June 30, 2026 --

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes